Immune Regulatory Oligonucleotides for TLR Antagonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune and inflammatory diseases, particularly those targeting tumor necrosis factor alpha (TNF-α), are limited by severe side effects such as infections and increased cancer risk, and there is a need for improved approaches to mitigate these issues while maintaining therapeutic efficacy.
Innovation Solution
Development of novel immune regulatory oligonucleotides (IROs) that act as antagonists of toll-like receptors (TLRs), allowing for the use of TNF-α inhibitors at lower dosages by potentiating their anti-inflammatory effects and reducing unwanted side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TNF-α inhibitors are used to treat autoimmune and inflammatory diseases, then therapeutic efficacy is improved, but severe side effects such as infections and increased cancer risk occur
Solution Approach 1:
The invention segments the immune response regulation by targeting specific Toll-like receptors (TLR2, TLR4, TLR9) rather than broadly suppressing TNF-α. This selective approach divides the immune modulation into specific pathways, achieving therapeutic efficacy while reducing off-target side effects such as infections and cancer risk associated with non-specific TNF-α inhibition.
Solution Approach 2:
The oligonucleotide compounds exhibit local quality by specifically binding to and modulating particular Toll-like receptors in immune cells. This localized action at the receptor level allows precise control of the immune response in affected tissues without causing systemic immunosuppression, thereby maintaining efficacy while minimizing harmful side effects.
2Reliability
If higher dosages of TNF-α inhibitors are administered to maintain therapeutic efficacy, then disease control is improved, but side effects increase
Solution Approach 1:
The invention changes the parameter of immune modulation from broad TNF-α suppression to specific TLR pathway regulation. By altering the mechanism from cytokine inhibition to receptor-level oligonucleotide binding, the therapy achieves effective disease control at lower dosages with reduced side effects, as the specific TLR-targeted approach is more efficient and less toxic than high-dose TNF-α inhibition.
3Adaptability or versatility
If non-specific medications are used to treat autoimmune diseases, then treatment coverage is broad, but effectiveness is limited
Solution Approach 1:
The oligonucleotide compounds possess multi-functionality by targeting multiple Toll-like receptors (TLR2, TLR4, TLR9) with a single class of agents. This universal approach provides broad treatment coverage across different autoimmune and inflammatory conditions while maintaining high effectiveness through the conserved role of TLRs in innate immunity, overcoming the limitations of non-specific medications.
Data Source
AI summary
The invention provides the use of immune regulatory oligonucleotides (IRO) as antagonist of TLRs and potentiators of anti-inflammatory agents that inhibit TNF for the prevention and treatment of inflammatory and autoimmune diseases.